ZINPLAVA
Biological
Merck Sharp & Dohme Corporation
Total Payments
$3.8M
Transactions
1,504
Doctors
527
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $243,876 | 5 | 0 |
| 2023 | $289,302 | 51 | 18 |
| 2022 | $440,905 | 84 | 41 |
| 2021 | $631,328 | 48 | 13 |
| 2020 | $265,399 | 147 | 41 |
| 2019 | $1.0M | 435 | 181 |
| 2018 | $654,642 | 486 | 172 |
| 2017 | $295,241 | 248 | 121 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 554 | 93.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $146,670 | 63 | 3.8% |
| Travel and Lodging | $57,071 | 172 | 1.5% |
| Consulting Fee | $31,624 | 36 | 0.8% |
| Food and Beverage | $31,000 | 627 | 0.8% |
| Education | $2,120 | 52 | 0.1% |
Payments by Type
Research
$3.6M
554 transactions
General
$268,485
950 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab MK-6072, Human Monoclonal Antibody to C. difficile Toxin B in Children Aged 1 to 18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection MODIFY III | Merck Sharp & Dohme Corporation | $769,157 | 0 |
| A Randomized Controlled Trial to compare the effectiveness of Fecal Microbiota Transplantation FMT in combination with Bezlotuxumab compared to FMT alone for the prevention of CDI recurrence in patients with Inflammatory Bowel Disease and Recurrent Clostridium difficile Infection | Merck Sharp & Dohme LLC | $632,327 | 0 |
| A Randomized Controlled Trial to compare the effectiveness of Fecal Microbiota Transplantation FMT in combination with Bezlotuxumab compared to FMT alone for the prevention of CDI recurrence in patients with Inflammatory Bowel Disease and Recurrent Clostridium difficile Infection | Merck Sharp & Dohme Corporation | $297,368 | 0 |
| A comparison of fidaxomicin and oral vancomycin for the treatment of Clostridium difficile infection CDI in hospitalized patients receiving concomitant antibiotics for the treatment of concurrent systemic infections | Merck Sharp & Dohme Corporation | $266,894 | 0 |
| Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab MK-6072, Human Monoclonal Antibody to C. difficile Toxin B in Children Aged 1 to less than 18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection MODIFY III | Merck Sharp & Dohme Corporation | $184,863 | 0 |
| Prevention of recurrent Clostridium difficile infection CDI in patients with inflammatory bowel disease IBD | Merck Sharp & Dohme Corporation | $165,057 | 0 |
| A Study to Evaluate the Immune Response to Clostridium difficile in Adult Immunosuppressed Patients with Clostridium difficile Infection | Merck Sharp & Dohme Corporation | $149,484 | 0 |
| A pragmatic trial of secondary prophylaxis with Bezlotoxumab to prevent C. difficile relapse among hospitalized adults receiving antibiotics. | Merck Sharp & Dohme Corporation | $141,400 | 0 |
| Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab MK-6072, Human Monoclonal Antibody to C. difficile Toxin B in Children Aged 1 to less than 18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection MODIFY III | Merck Sharp & Dohme LLC | $124,465 | 0 |
| A prospective, double-blind, randomized, and controlled clinical trial to compare the effectiveness of intravenous Bezlotoxumab 10 mg,kg versus placebo in decreasing morbidity and mortality in patients with fulminant Clostridioides difficile requiring surgical intervention. | Merck Sharp & Dohme Corporation | $123,147 | 0 |
| Historically-controlled clinical trial of the efficacy and safety of bezlotoxumab BELZO in addition to standard of care SOC vancomycin for the treatment of multi-recurrent Clostridium difficile infection | Merck Sharp & Dohme Corporation | $108,816 | 0 |
| Prevention of recurrent Clostridium difficile infection (CDI) in patients with inflammatory bowel disease (IBD) | Merck Sharp & Dohme LLC | $98,800 | 0 |
| STUDY NAMEEarly Experience with Bezlotoxumab in Reducing Recurrence of Clostridium difficile Infection in Immunocompromised Patients at a Tertiary Care Center | Merck Sharp & Dohme Corporation | $87,017 | 0 |
| The effects C. difficile toxins on human in vitro multicellular models systems | Merck Sharp & Dohme Corporation | $58,882 | 0 |
| Protocol Title# A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab MK-6072, Human Monoclonal Antibody to C. difficile Toxin B in Children Aged 1 to less than 18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection MODIFY III | Merck Sharp & Dohme LLC | $50,282 | 0 |
| STUDY NAME#How does passive immunoglobulin effect C. difficile toxin A and B binding and host barrier response | Merck Sharp & Dohme Corporation | $47,402 | 0 |
| How does passive immunoglobulin effect C. difficile toxin A and B binding and host barrier response | Merck Sharp & Dohme Corporation | $42,922 | 0 |
| Prevention of recurrent Clostridium difficile infection (CDI) in patients with inflammatory bowel disease (IBD) | Merck Sharp & Dohme Corporation | $38,000 | 0 |
| Early Experience with Bezlotoxumab in Reducing Recurrence of Clostridium difficile Infection in Immunocompromised Patients at a Tertiary Care Center | Merck Sharp & Dohme Corporation | $37,293 | 0 |
| Real-world evaluation of bezlotoxumab for the management of Clostridioides difficile infection | Merck Sharp & Dohme Corporation | $27,210 | 0 |
Top Doctors Receiving Payments for ZINPLAVA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Infectious Disease | Alhambra, CA | $125.00 | 1 |
| , M.D | Internal Medicine | Brooklyn, NY | $125.00 | 1 |
| , MD | Infectious Disease | San Antonio, TX | $124.99 | 1 |
| , MD | Gastroenterology | San Antonio, TX | $124.99 | 1 |
| , MD | Internal Medicine | Houston, TX | $124.99 | 1 |
| , MD | Internal Medicine | Lackland A F B, TX | $124.99 | 1 |
| , DO | Internal Medicine | Fort Sam Houston, TX | $124.99 | 1 |
| , MD | Internal Medicine | Houston, TX | $124.99 | 1 |
| , M.D | Internal Medicine | Fort Sam Houston, TX | $124.99 | 1 |
| , M.D | Infectious Disease | Houston, TX | $124.99 | 1 |
| , M.D | Infectious Disease | San Antonio, TX | $124.99 | 1 |
| , M.D | Gynecologic Oncology | Columbus, OH | $124.83 | 1 |
| , MD | Gastroenterology | Hilliard, OH | $124.83 | 1 |
| , M.D | Specialist | Westerville, OH | $124.83 | 1 |
| , M.D | Gynecology | Columbus, OH | $124.83 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Columbus, OH | $124.83 | 1 |
| , MD | Infectious Disease | Lexington, KY | $123.83 | 1 |
| , MD | Infectious Disease | Lexington, KY | $123.83 | 1 |
| , M.D | Infectious Disease | Lexington, KY | $123.83 | 1 |
| , MD | Colon & Rectal Surgery | Lexington, KY | $123.83 | 1 |
| , M.D | Internal Medicine | Lexington, KY | $123.83 | 1 |
| , MD | Infectious Disease | Lexington, KY | $123.83 | 1 |
| , M.D | Internal Medicine | Houston, TX | $123.76 | 1 |
| , DO | Pediatrics | Houston, TX | $123.76 | 1 |
| , M.D | Pulmonary Disease | New York, NY | $123.04 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $2.9M
- Merck Sharp & Dohme LLC $974,083
Product Information
- Type Biological
- Total Payments $3.8M
- Total Doctors 527
- Transactions 1,504
About ZINPLAVA
ZINPLAVA is a biological associated with $3.8M in payments to 527 healthcare providers, recorded across 1,504 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $243,876 was paid across 5 transactions to 0 doctors.
The most common payment nature for ZINPLAVA is "Unspecified" ($3.6M, 93.0% of total).
ZINPLAVA is associated with 20 research studies, including "Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab MK-6072, Human Monoclonal Antibody to C. difficile Toxin B in Children Aged 1 to 18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection MODIFY III" ($769,157).